Zhejiang Anglikang Pharmaceutical Co Ltd Class A (002940) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.062x

Based on the latest financial reports, Zhejiang Anglikang Pharmaceutical Co Ltd Class A (002940) has a cash flow conversion efficiency ratio of 0.062x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥112.57 Million ≈ $16.47 Million USD) by net assets (CN¥1.83 Billion ≈ $267.16 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Zhejiang Anglikang Pharmaceutical Co Ltd Class A - Cash Flow Conversion Efficiency Trend (2014–2024)

This chart illustrates how Zhejiang Anglikang Pharmaceutical Co Ltd Class A's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Zhejiang Anglikang Pharmaceutical Co Ltd debt and liabilities for a breakdown of total debt and financial obligations.

Zhejiang Anglikang Pharmaceutical Co Ltd Class A Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Zhejiang Anglikang Pharmaceutical Co Ltd Class A ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Nabors Industries Ltd F:NBI1	0.171x
Daishin Sec KO:003540	-0.415x
Ningbo Donly Co Ltd SHE:002164	0.028x
ALPHAMAB ONCOLO.DL-000002 F:3NK	N/A
Biotest Aktiengesellschaft XETRA:BIO	-0.114x
Triveni Engineering & Industries Limited NSE:TRIVENI	0.012x
Qisda Corp TW:2352	0.051x
Brookline Bancorp Inc NASDAQ:BRKL	0.027x

Annual Cash Flow Conversion Efficiency for Zhejiang Anglikang Pharmaceutical Co Ltd Class A (2014–2024)

The table below shows the annual cash flow conversion efficiency of Zhejiang Anglikang Pharmaceutical Co Ltd Class A from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see Zhejiang Anglikang Pharmaceutical Co Ltd market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	CN¥1.80 Billion ≈ $263.17 Million	CN¥253.60 Million ≈ $37.11 Million	0.141x	-6.69%
2023-12-31	CN¥1.83 Billion ≈ $268.12 Million	CN¥276.91 Million ≈ $40.52 Million	0.151x	+34.66%
2022-12-31	CN¥1.65 Billion ≈ $240.88 Million	CN¥184.75 Million ≈ $27.03 Million	0.112x	-16.25%
2021-12-31	CN¥1.47 Billion ≈ $215.83 Million	CN¥197.65 Million ≈ $28.92 Million	0.134x	-7.03%
2020-12-31	CN¥1.38 Billion ≈ $201.64 Million	CN¥198.61 Million ≈ $29.06 Million	0.144x	-31.38%
2019-12-31	CN¥1.02 Billion ≈ $148.74 Million	CN¥213.49 Million ≈ $31.24 Million	0.210x	+52.63%
2018-12-31	CN¥970.93 Million ≈ $142.08 Million	CN¥133.61 Million ≈ $19.55 Million	0.138x	-71.99%
2017-12-31	CN¥394.37 Million ≈ $57.71 Million	CN¥193.77 Million ≈ $28.36 Million	0.491x	+13.50%
2016-12-31	CN¥327.43 Million ≈ $47.91 Million	CN¥141.74 Million ≈ $20.74 Million	0.433x	-17.47%
2015-12-31	CN¥264.20 Million ≈ $38.66 Million	CN¥138.59 Million ≈ $20.28 Million	0.525x	+125.68%
2014-12-31	CN¥217.08 Million ≈ $31.77 Million	CN¥50.46 Million ≈ $7.38 Million	0.232x	--

About Zhejiang Anglikang Pharmaceutical Co Ltd Class A

SHE:002940 China Drug Manufacturers - Specialty & Generic

Market Cap

$976.49 Million

CN¥6.67 Billion CNY

Market Cap Rank

#9211 Global

#2481 in China

Share Price

CN¥33.08

Change (1 day)

-3.19%

52-Week Range

CN¥13.36 - CN¥64.70

All Time High

CN¥249286.54